For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for Incyte Corporation (INCY) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-08-23): Designation Watch · Gem Score -6 (−100…+100 Quality+Value blend) · Quality 42 · Value -46 · Sentiment 26 (timing only, not weighted) · Composite fair value $105.98 vs $122.99 at analysis
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
Incyte Corporation
INCY NASDAQIncyte Corporation is a biopharmaceutical company that focuses on the discovery, development, and commercialization of proprietary therapeutics for serious medical conditions. The company concentrates on hematology and oncology, as well as inflammation, autoimmunity, and dermatology, addressing diseases with significant unmet medical needs. A core part of its business is small-molecule drug development, supported by a broad pipeline of oncology and dermatology programs. Incyte’s portfolio includes Jakafi for certain rare blood cancers and graft-versus-host disease, along with partnered and licensed therapies such as Olumiant for rheumatoid arthritis, Iclusig for chronic myeloid leukemia, Pemazyre for cholangiocarcinoma, Tabrecta for lung cancer, and Monjuvi for diffuse large B-cell lymphoma. The company also markets Opzelura, a topical treatment for atopic dermatitis and vitiligo in dermatology. Founded in 1991 and headquartered in Wilmington, Delaware, Incyte plays a notable role in the healthcare and biotechnology sectors by providing targeted therapies that are integrated into specialized care across global markets.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 6.41
Total Equity: $5.17B
Shares: 200,700,000
Total Debt: $0.00
Cash: $3.10B
EBITDA: $1.61B
Total Debt: $0.00
Cash: $3.10B
Revenue: $5.14B
Revenue: $5.14B
Revenue: $5.14B
Total Equity: $5.17B
Tax Rate: 22.7%
Equity: $5.17B
Total Debt: $0.00
Cash: $3.10B
Current Liabilities: $1.52B
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $5.17B
Shares: 200,700,000
Shares: 200,700,000
CapEx: $0.00
Shares: 200,700,000
Stock Price: $123.16
Net Income: $1.29B
Industry Benchmarks
Income Statement (Annual)
Last updated: Jul 30, 2026 7:19pm (24d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $3.0B | $3.4B | $3.7B | $4.2B | $5.1B |
| Cost of Revenue | $151.0M | $207.0M | $255.0M | $312.1M | $372.1M |
| Gross Profit | $2.8B | $3.2B | $3.4B | $3.9B | $4.8B |
| Operating Expenses | $2.2B | $2.6B | $2.8B | $3.9B | $3.3B |
| Operating Income | $585.8M | $579.4M | $620.5M | $61.4M | $1.5B |
| Net Income | $948.6M | $340.7M | $597.6M | $32.6M | $1.3B |
| EBITDA | $643.6M | $647.3M | $703.2M | $150.6M | $1.6B |
| EPS | $4.30 | $1.53 | $2.67 | $0.16 | $6.59 |
| EPS (Diluted) | $4.27 | $1.52 | $2.65 | $0.15 | $6.41 |
Balance Sheet (Annual)
Last updated: Jul 30, 2026 6:56pm (24d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $2.1B | $3.0B | $3.2B | $1.7B | $3.1B |
| Total Current Assets | $3.1B | $4.1B | $4.6B | $3.2B | $5.0B |
| Total Assets | $4.9B | $5.8B | $6.8B | $5.4B | $7.0B |
| Current Liabilities | $854.3M | $1.2B | $1.2B | $1.6B | $1.5B |
| Long-Term Debt | — | — | — | — | — |
| Total Liabilities | $1.2B | $1.5B | $1.6B | $2.0B | $1.8B |
| Total Equity | $3.8B | $4.4B | $5.2B | $3.4B | $5.2B |
| Retained Earnings | -$777.9M | -$437.2M | $160.4M | -$1.1B | $213.8M |
Cash Flow (Annual)
Last updated: Jul 30, 2026 7:19pm (24d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $749.5M | $969.9M | $496.5M | $335.3M | $1.4B |
| Capital Expenditure | -$181.0M | -$77.8M | — | — | — |
| Free Cash Flow | $568.5M | $892.1M | — | — | — |
| Acquisitions (net) | — | — | — | — | — |
| Net Debt Issued / (Repaid) | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | — | $0 | $0 | -$2.0B | $0 |
| Net Change in Cash | $544.4M | $894.0M | $262.1M | -$1.5B | $1.4B |
Growth Trends (YoY %)
Last updated: Jul 30, 2026 7:19pm (24d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +13.7% | +8.9% | +14.8% | +21.2% |
| Gross Profit Growth | +12.4% | +7.9% | +14.2% | +21.4% |
| Operating Income Growth | -1.1% | +7.1% | -90.1% | +2,368.6% |
| Net Income Growth | -64.1% | +75.4% | -94.5% | +3,845.0% |
| EBITDA Growth | +0.6% | +8.6% | -78.6% | +967.7% |
Deep Analysis
Risk : Reward — if the last quarter repeats
Live · as of 2026-08-19 09:00| Case | Growth | Margin | Fair value | vs price ($122.99) |
|---|---|---|---|---|
| Bull — recovery | +35% | 30.7% | $258.28 | +110% |
| Base — stabilizes | +24% | 26.7% | $162.41 | +32% |
| Bear — keeps slipping | +12% | 22.7% | $98.35 | -20% |
| Stress — last quarter repeats | +16% | 26.7% | $131.24 | +7% |
Narrative Economics
market-narrative step).
Claude Reading
Looking at the raw numbers first: revenue went from $3.39B (2022) → $3.70B (2023) → $4.24B (2024) → $5.14B (2025), a genuine acceleration, not deceleration. The 2024 operating income collapse to $61M was almost certainly an IPR&D writedown (the Q2'24 -$444M net loss print supports this) — not operational deterioration. Strip that out and 2024 op income was ~$500M+, meaning 2025's $1.51B operating income represents real ~3x expansion, likely from Opzelura ramp and Jakafi price/volume. Q1'26 revenue of $1.27B is up 21% YoY vs Q1'25's $1.05B, and margins have stabilized in the 20-33% range across the last four quarters. This is not a decelerating business; the "decelerating quarterly trend" flag looks like noise from lumpy R&D milestones.
That said, I'm skeptical of the earnings CAGR (46.7%) and FCF CAGR (68.7%) figures — these are optically inflated by the 2024 impairment trough. Normalized earnings growth is probably 15-20%, which is still respectable but doesn't justify treating this as a compounder. The real question — which every model dances around but none prices rigorously — is Jakafi's 2028 patent cliff. Jakafi is roughly 60-65% of revenue. Even with Opzelura growing (~$500M run-rate and climbing) and pipeline assets like axatilimab and mutant-CALR programs, a 40-50% revenue haircut in 2028-2029 is a live scenario. At 4.8x sales and 19x earnings, you are not being paid to underwrite that risk with much margin.
Where I disagree with the model stack: the Synthesis says "fair value" at signal-adjusted $116 vs $123, and Market Forces calls it "Tailwinds." These two are in mild tension — you don't get tailwinds AND a 6% overvaluation simultaneously unless the tailwind is already priced. The Narrative layer nails it better: fundamentals are doing 94% of the work, the "steady compounder" story adds a thin premium. Pre-Flight's claim that the market is "skeptical about durability" at 19x P/E is wrong — 19x for a company facing a 2028 cliff on 60% of revenue is not skeptical, it's roughly appropriate to slightly generous. If the market were truly skeptical, INCY would trade at 12-14x like other pre-cliff pharma names (see BMY, PFE). The insider activity is uninformative — F-InKind is tax withholding on vested RSUs, and the single 28k share sale is small relative to float. Neutral is correct.
A contrarian bull argues: Opzelura's TAM in atopic dermatitis and vitiligo is $2-3B+ peak, currently underappreciated; the mutant-CALR program in myelofibrosis could partially offset Jakafi erosion in Incyte's core franchise; and $3.1B cash with zero debt gives optionality for tuck-in M&A to buy pipeline. If Opzelura reaches $1.5B by 2027 and pipeline adds $500M, the cliff becomes a speed bump, not a canyon. Under that scenario, 2027 EPS could hit $8-9 and a re-rate to 18x gets you $150. A contrarian bear counters: JAK-class safety labels (black box on cardiovascular events) cap Opzelura penetration, biosimilar Jakafi launches in Europe are already pressuring 2026 numbers, and every mid-cap biotech at this stage of lifecycle has said "the pipeline will offset the cliff" — most don't. Look at Biogen post-Tecfidera or Gilead post-HCV. My read: the bear case has better historical base rates.
GPT Reading
What jumps out first is that Incyte’s income statement has inflected much harder than the “mature earner” label suggests, but the market is already paying for a good chunk of that repair. Revenue went from $4.24B in 2024 to $5.14B in 2025, up 21%, while operating income exploded from just $61M to $1.51B and net income from $33M to $1.29B. That is not a sleepy large-cap pharma profile; it is a company coming out of a depressed earnings year and re-establishing a very high-margin earnings base. The quarterly sequence reinforces that point: after the ugly June 2024 quarter with a -42.6% net margin, Incyte put up margins of 9.4%, 17.1%, 15.0%, 33.3%, 31.1%, 19.9%, and 23.8% over the next seven quarters. On a trailing four-quarter basis from the data here, revenue is roughly $5.37B and net income about $1.43B, so the current $24.96B market cap implies roughly 17-18x trailing earnings and about 4.6x trailing sales. For a debt-free biotech with $3.10B cash and $1.41B operating cash flow, that is not expensive in a vacuum.
But the pattern inside the quarters matters. Revenue growth is real, yet it is no longer accelerating cleanly. The quarterly revenue base climbed from $1.04B in 2Q24 to $1.18B, $1.05B, $1.22B, $1.37B, $1.51B, then slipped to $1.27B in 1Q26. Some of that is normal seasonality or milestone noise, but it weakens the idea that the 2025 earnings step-up should be capitalized as a smooth new run-rate. Net income tells the same story: $405M and $424M in mid/late 2025 were excellent, but the following two quarters were closer to $299M and $303M. That still annualizes to a healthy $1.2B+, yet it argues for normalization rather than extrapolation. At $123, investors are getting a high-quality, cash-rich commercial biotech, but not a bargain if earnings settle around the recent $1.2B-$1.4B zone. Adjusting market cap for net cash gives an enterprise value around $21.9B; against 2025 operating income of $1.51B that is about 14.5x EV/EBIT, a fair multiple for a durable pharma asset base but not one screaming mispricing.
The strongest positive in the data is balance-sheet quality and the absence of financial strain. Zero debt, current ratio above 3.3x, $3.10B of cash, 92.8% gross margin, and 29.5% operating margin give management a lot of room to absorb pipeline volatility, buy back stock, or do business development. Just as important, this is not a story where accounting earnings vastly outrun cash generation: $1.41B of operating cash flow against $1.29B of net income in 2025 is solid. ROE of 24.9%, ROA of 18.5%, and especially reported ROIC of 56.6% are unusually strong and support the view that the core portfolio remains economically excellent today. So while I do not think the shares are materially cheap, I also do not buy a bearish “melting ice cube” framing from this dataset. The business has plainly earned a premium to commodity biotech multiples.
The best argument against my caution is that I may be over-penalizing quarter-to-quarter lumpiness in a business where commercial leverage is now obvious. If 2025 is the right baseline rather than an exceptional year, then 19x annual earnings for a debt-free biotech growing revenue 20%+ is too low, not too high. A bull would cite the move from $3.70B revenue and $598M net income in 2023 to $5.14B and $1.29B in 2025, plus the latest quarter’s 21% year-over-year revenue growth and 23.8% net margin, and say the stock deserves something closer to 22-24x earnings. On that math, equity value could justify something in the mid-$130s to low-$150s, especially if investors gain confidence that 2024 was a one-off trough and not a warning about franchise durability. I weigh that case lower because the reported data do not show a clean upward slope in the most recent three quarters, and because a company trading near 5x sales with visible product concentration risk usually needs either sustained growth acceleration or a stronger catalyst set than appears in these numbers alone.
What would change my mind is simple. If the next two quarters re-establish a clear growth path — revenue consistently above $1.35B and net income back above $350M without one-time help — then I would treat 2025 as the true earnings base and become more constructive even above $123. Conversely, if revenue stalls around $1.2B-$1.25B and margins drift back toward the mid-teens, then today’s multiple is too generous and fair value is closer to the low $100s. For now, I see a very good company priced around fair value, with quality and cash offset by enough trajectory uncertainty that the upside from here looks limited unless execution re-accelerates.
Grok Reading
Incyte’s 2025 results mark a decisive break from the prior year’s near-zero profitability: revenue climbed to $5.14B from $4.24B (+21%), operating income surged from $61M to $1.51B, and net income reached $1.29B for a 25% net margin. That is not a one-quarter fluke; the last four reported quarters delivered $1.05B, $1.22B, $1.37B and $1.51B before a seasonal step-down to $1.27B in Q1 2026, still +21% year-over-year. Gross margin sits at 93%, operating margin at 29.5%, ROIC at an exceptional 56.6%, and the balance sheet carries $3.1B cash against zero debt. Operating cash flow of $1.41B funds the entire franchise without leverage. At 19.2x trailing earnings, 13x EV/EBITDA and 4.1x EV/sales, the market is paying a mature-pharma multiple for a business still compounding revenue at an 18% CAGR and earnings far faster. The story the numbers tell is a high-quality, cash-generative JAK franchise that has already absorbed whatever one-time charges wrecked 2024 and is now running at peak efficiency.
Sequential revenue did decelerate into Q1 2026 and the secondary signals flag a decelerating quarterly trend, yet the absolute level remains well above the $1.0–1.2B range of 2024–early 2025. Insider activity is almost entirely tax-withholding “F-InKind” transactions plus a single modest sale—neutral, not a red flag. The 46.7% earnings CAGR and 68.7% FCF CAGR over the multi-year window confirm that operating leverage is real once the company is past non-recurring items. With ROE at 25% and a current ratio above 3.3, capital returns or bolt-on pipeline deals are fully funded. This is a mature earner trading like one, not a speculative biotech.
The strongest counter-argument is the Jakafi patent cliff in 2028–2029 and the valuation models’ $116 signal-adjusted fair value versus the $123 print. A smart opponent will note that the entire 25% net-margin machine still leans heavily on one asset, that Opzelura and the rest of the portfolio have yet to prove they can fully replace it, and that 19x earnings leaves little room if growth slows further or clinical catalysts disappoint. The “priced-for-perfection” label is overstated—true perfection pricing would be closer to 28–30x—but the 5–6% premium to the composite fair-value estimate is real, and crowded competitive dynamics in JAK inhibitors (Lilly, others) could compress share faster than the street models. I weigh these risks as already partially discounted in the multiple and more than offset by the fortress balance sheet and current cash generation; the cliff is two-plus years out and the company is throwing off >$1.4B of operating cash annually to bridge it.
What would flip the view is either a clear acceleration in non-Jakafi revenue (Opzelura run-rate or a pipeline readout that de-risks 2029+ sales) pushing trailing growth back above 25%, or conversely a second consecutive quarter of sub-10% year-over-year growth accompanied by margin compression below 20%. A material capital-return announcement or a value-accretive BD deal funded by the $3.1B cash pile would also shift the risk-reward decisively higher.
Big-3 Panel — where each AI stands
Advanced Analysis Forensic deep-dive · separate lenses
Incyte is a mature, self-funding biotech: 2025 revenue of $5.14B (up from $2.99B in 2021, ~14% CAGR), gross margins consistently ~93%, $3.10B liquid cash with essentially no debt (net cash $3.10B), Altman Z of 10.47, and $1.41B of FCF. Earnings quality is clean - OCF/NI of 3.17x and accruals of -2.5% of assets suggest reported earnings are backed by cash, not accruals. Diluted share count has actually shrunk from 225.9M (2023) to 200.7M (2025), a ~-2.5% CAGR, with buybacks running 181.8% of SBC - genuine per-share value concentration, rare for biotech. However, the operating margin path is jarring: 19.6% (2021) to 17.1% to 16.8% to 1.4% (2024) then snapping back to 29.5% (2025). Net income swung from $948M to $341M to $598M to $33M to $1.29B. That 2024 collapse and 2025 rebound almost certainly reflect large R&D/IPR&D charges or milestone accounting rather than steady-state economics - the underlying business is more volatile than the headline 2025 print suggests. Jakafi concentration and patent-cliff exposure are the structural questions the numbers cannot answer. Insider tape is neutral-to-slightly-negative: only F-InKind tax withholdings and one $3.2M open-market sale by Stein, zero open-market buys in 12 months. Not alarming for a large-cap biotech but no conviction signal either.
Verify before trusting this (5)
- What drove the 2024 operating margin collapse to 1.4% - IPR&D charge, impairment, or milestone payment?
- Jakafi revenue concentration and years remaining on key patents/exclusivity
- Pipeline diversification: revenue contribution from Opzelura, Monjuvi, and newer approvals
- Terms and pace of the buyback authorization - is the -2.5% share count trend sustainable?
- R&D productivity: recent Phase 3 readouts and regulatory milestones
The e2e composite fair value lands at $99.53 and the signal-adjusted FV at $116.05, both below the $122.99 price, implying roughly -6% to -19% downside to deserved value. The per-method spread is telling: the EPV floor sits at $38.84 (a punitive no-growth read reflecting lumpy operating margins) while an anchored-PE method reaches $160.22 (assuming the good years are the run-rate). The truth sits between, and the composite $100 is a reasonable skeptical center given the operating-margin whiplash flagged by the quality lens. Earnings quality is high, so no additional haircut is warranted, but that already-clean signal is embedded in the FV. The bull case (durable Jakafi cash, pipeline optionality, buybacks) is largely priced in; the bear (Jakafi LOE, crowded JAK competition) is not. Buying here means paying full retail for a strong-but-concentrated specialty biotech with a known franchise cliff. Margin of safety is negative. This is a fine business at a slightly rich price - not a short, not a buy on valuation.
Verify before trusting this (4)
- Jakafi LOE timing and generic entry assumptions in guidance
- Segment-level operating margin trajectory - is the 29.5% year repeatable or one-off
- Pipeline readouts that would materially shift deserved value (Opzelura expansion, oncology assets)
- Buyback pace and remaining authorization
The macro tape is stressed (VIX 20.7, S&P off highs, 10y at 4.61%), but INCY's 0.76 beta and defensive biotech profile mute that pressure meaningfully. This is not a high-multiple story stock getting de-rated in risk-off; it is a steady-compounder with minimal narrative intensity, so there is no euphoric premium to unwind and no cult to crack. The macro headwind lands here as a light crosswind, not a body blow. Company-specific news flow this week is net positive: a Q2 beat with revenue up 38-40%, 2026 guidance raised on the top line, and the EU nod for Opzelura in atopic dermatitis - the first steroid-free topical JAK approval in Europe. Headlines note shares slipped intraday on a softer segment of guidance and post a big up-day, but the aggregate tone from analysts and trade press is constructive: earnings beat by 54%, revenue beat by 15%, pipeline advancing. Narrative-wise, the story is durable but quiet - fundamentals are doing ~94% of the valuation work, so sentiment cannot press hard in either direction. Net: a mild tailwind from the earnings/approval news cycle, dampened by a hostile broad tape that INCY only partially feels.
Verify before trusting this (4)
- Whether analyst target revisions post-print skew up (confirming tailwind) or focus on the softer guidance line
- VIX trajectory - a sustained move above 22 would start pressuring even low-beta names
- Jakafi genericization/patent-cliff headlines - the one narrative crack that could flip sentiment
- Sector rotation signals in XBI/IBB relative to SPX
This lens hasn't been run for this ticker yet.
When we made this prediction on Aug 1, 2026, INCY was $119.52. We expect it to be $113.50 by Feb 2027, and we consider it great value under $95.00. This is an early model (v0.6.0) — the direction is more reliable than the exact price. Made Aug 1, 2026.
Blue is our prediction, starting the day we made it. Grey is a slower route to the same place — the same destination, taking longer. Black is the actual price, so you can see how we are doing.